Back

Lp(a): should we go after it? Should it modify our lipid targets?

28 August 2017 (16:48 - 17:06)
Organised by:
Congress Presentation Part of: The Primary Prevention Summit Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail
SPRINT and HOPE3: implications for the treatment of hypertension.
Doctor S. Yusuf (Hamilton, CA)
Slides Video
Presentation thumbnail
How much exercise is needed to prevent heart disease?
Doctor C. Lavie (New Orleans, US)
Slides Video
Presentation thumbnail
"Statins for life"? The effect of statins on survival in primary prevention.
Professor P. Greenland (Chicago, US)
Slides Video
Presentation thumbnail
"Plaque but no obstructive coronary disease" - Primary or secondary prevention?
Professor S. Halvorsen (Oslo, NO)
Slides Video

Access the full session

Session thumbnail
The Primary Prevention Summit

The Event

Event poster

ESC Congress 2017

28 August 2017 16:48 CET
You may be interested in
thumbnail
Webinar
Lipoprotein(a): current role and future perspectives in cardiovascular medicine
31 October 2025
thumbnail
Congress Presentation
Variability of lipoprotein(a) levels in patients hospitalized in an emergency setting
24 April 2026
thumbnail
Congress Presentation
EAS Consensus on Lp(a) 2022- What to measure, in whom to measure, how to interpret and what to do - Q&A .
29 August 2022
thumbnail
Congress Presentation
The prevalence and accumulation of main cardiometabolic risk factors among the finnish adult population at different levels of lp(a)
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources